Brief: RenovoRx Announces Initial Results In Pharmacokinetic Substudy
18/01/2023 14:07
Jan 18 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ANNOUNCES INITIAL RESULTS IN PHARMACOKINETIC (PK)
SUBSTUDY: DATA ON RENOVOGEM™ SUPPORTS POTENTIAL FOR RENOVOTAMP®
THERAPY PLATFORM TO INCREASE LOCAL GEMCITABINE (CHEMOTHERAPY)
DELIVERY AND DECREASE SIDE EFFECTS OF PANCREATIC CANCER
TREATMENT
Source text for Eikon: ID:nBwbG5Zzta
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer